HIV-1 peptide vaccine candidates: selecting constrained V3 peptides with highest affinity to antibody 447-52D.
The V3 region of the envelope glycoprotein gp120 of the human immunodeficiency virus type 1 (HIV-1) is a potential target for an anti-HIV-1 vaccine. Peptides corresponding to V3 form three variations of a beta-hairpin conformation when bound to anti-V3 HIV-1 neutralizing antibodies. The conformation of a V3(IIIB) peptide bound to the 0.5beta antibody, generated against an X4 gp120, has been postulated to represent the V3 conformation of X4 viruses while the conformations of a V3(MN) and a V3(CONSENSUS) peptide bound to the 447-52D human monoclonal antibody were postulated to represent the R5A and R5B V3 conformations of R5 viruses, respectively. To constrain the conformation of synthetic V3 peptides to these X4, R5A, and R5B conformations, we formed disulfide bonds between Cys residues whose location in a peptide template representing the entire V3(CONSENSUS) epitope recognized by the broadly neutralizing 447-52D antibody was changed systematically. In a previous study [Mor, A., et al. (2009) Biochemistry 48, 3288-3303] we showed that these constrained peptides adopted conformations resembling the three antibody-bound V3 conformations according to the location of the disulfide bonds. Here we show that these constrained peptides, with the exception of peptides in which the disulfide bond flanks the GPGR segment, retain high-affinity binding to the 447-52D antibody. Compared with peptides designed to mimic the X4 conformation, peptides designed to mimic either the R5A or R5B conformation had higher affinity to 447-52D. It is possible that constrained peptides which mimic the R5A and R5B conformations of the V3 and retain high-affinity binding to 447-52D are good candidates for eliciting a broad neutralizing antibody response similar to that of 447-52D.
Mester
Brenda
B
Department of Structural Biology, Weizmann Institute of Science, Rehovot 76100, Israel.
Manor
Revital
R
Mor
Amit
A
Arshava
Boris
B
Rosen
Osnat
O
Ding
Fa-Xiang
FX
Naider
Fred
F
Anglister
Jacob
J
D016915:AIDS Vaccines / Q000138:chemical synthesis / Q000276:immunology / Q000378:metabolism*; D000911:Antibodies, Monoclonal / Q000378:metabolism*; D000915:Antibody Affinity; D001666:Binding Sites, Antibody; D015699:HIV Envelope Protein gp120 / Q000138:chemical synthesis / Q000276:immunology / Q000378:metabolism; D015497:HIV-1 / Q000276:immunology / Q000302:isolation & purification; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000378:metabolism; D007135:Immunoglobulin Variable Region / Q000378:metabolism*; D009500:Neutralization Tests; D010446:Peptide Fragments / Q000138:chemical synthesis / Q000276:immunology / Q000378:metabolism*; D011485:Protein Binding / Q000276:immunology; D011487:Protein Conformation; D022223:Vaccines, Subunit / Q000737:chemistry / Q000276:immunology / Q000378:metabolism
D016915:AIDS Vaccines; D000911:Antibodies, Monoclonal; D015699:HIV Envelope Protein gp120; D007140:Immunoglobulin Fab Fragments; D007135:Immunoglobulin Variable Region; D010446:Peptide Fragments; D022223:Vaccines, Subunit